



CIN No. L24232PB1983PLC005426

GST No. 03AAACK6458M1ZB

D.L. No. 1800-OSP, 1804-B

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitiypharma.com
ramesh@kwalitiypharma.com
Website : www.kwalitiypharma.com

Management Discussion and Analysis — Q1 FY27

Kwaliti Pharmaceuticals Ltd. ("KPL") delivered a strong start to FY27, extending its track record of disciplined execution, expanding regulatory footprint, and growing presence in complex, high-barrier product segments.

In Q1FY27, consolidated revenue grew 46% year-on-year to ₹162 crore from ₹112 crore in Q1FY26, and rose 3% QoQ from ₹157 crore in Q4FY26. EBITDA increased to ₹41 crore from ₹37 crore in Q1FY26, an increase of 13% YoY, with margins expanding from 21.9% to 25.3% (up from 24.8% in Q4FY26), reflecting continued operating leverage and a stronger product mix. PAT surged 119% YoY to ₹26 crore from ₹12 crore, with margins improving sharply from 11% to 16%; on a QoQ basis, PAT grew 3% with margins holding steady at 16%. Building on this momentum and a strong FY26 base, management has raised FY27 guidance across all key metrics: revenue to ₹700+ crore (+39%+ YoY), EBITDA to ₹189–196+ crore (27–28%+ margin), and PAT to ₹109+ crore (~15.5%+ margin).


During the quarter, KPL advanced its R&D and clinical programme, completing **13 Bioequivalence (BE) studies** — 7 from the General unit, 2 from Beta Lactam, and 4 from Oncology as part of its **40 molecule BE programme (including 3 injectables and 37 OSDs)**. Filings for completed BE studies have already been made in 15+ countries, with further filings underway, reinforcing KPL's push into regulated markets.

The company also secured **15+ new key product registrations** during the quarter across **Malaysia, Algeria, Peru and Mexico**.

On the biologics front, KPL received **approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate alongside Erythropoietin**, which has now progressed to the clinical trial stage.

Construction of the Hormone manufacturing facility remains on schedule, with completion anticipated by **November 2026**.

The company operates five state-of-the-art manufacturing facilities, accredited by premier global regulators such as PIC/S (including ANVISA and SFDA), INVIMA, DIGEMID, and EU-GMP. This robust regulatory foundation establishes KPL as a research-driven front runner in complex and niche injectables, with a presence in over 70+ countries.





VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.



CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 16/8/26

**INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY UNAUDITED
STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30TH
JUNE , 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To,

**The Board of Directors of
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Kwality Pharmaceuticals Limited ("the company) for the quarter ended on 30th June , 2026**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com





VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.



CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 12/8/2026

performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VIJAY MEHRA & CO.

Chartered Accountants

CA AMIT HANDA

Partner

M. No: 502400

FRN: 001051N

UDIN:-26502400AYBZEH2450



Place: Amritsar

Date: 10-08-2026

BRANCH OFFICES:

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagcel@gmail.com



VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A, B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 10/01/26

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE, 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

**The Board of Directors of
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Kwality Pharmaceuticals Limited ("the Parent")** and its subsidiary (the Parent and its subsidiary together referred to as **"the Group"**), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter ended on **30th June 2026** being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to the extent

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com





VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Date : 10/8/2026

Ref: _____

applicable.

4. The Statement includes the results of the following entities:

Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of consolidated unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("IndAs") and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of subsidiary which have not been reviewed/audited by us, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. **0.00** Lacs for the quarter ended 30th June, 2026, total Profit/(loss) after tax of Rs. **-0.45 Lacs** and total other comprehensive income / loss of Rs. **-0.45 Lacs** for the quarter ended 30th June, 2026 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For VIJAY MEHRA & CO.

Chartered Accountants

CA AMIT HANDA

Partner

M. No: 502400

FRN: 001051N

UDIN:- 26502400YTRLYD1265



Place: Amritsar

Date: 10-08-2026

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@ gmail.com, caamithanda@ gmail.com, caashishraja09@ gmail.com, caradhikagoel@ gmail.com

KWALITY PHARMACEUTICALS LIMITED Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PUNJAB – 143601 CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862 Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com					
Unaudited Standalone Financial Results for the Quarter Ended 30th June 2026					
(` in lakhs) except EPS					
Sr. No.	Particulars	Quarter Ended 30.06.2026 (Unaudited)	Quarter Ended 31.03.2026 (Audited)	Quarter Ended 30.06.2025 (Unaudited)	Year Ended 31.03.2026 (Audited)
I	Revenue from operations (Net)	16235.22	15682.24	11147.90	50305.89
II	Other income	62.27	105.80	37.57	285.86
III	Total Revenue (I+II)	16297.49	15788.04	11185.47	50591.75
IV	Expenses				
	(a) Cost of materials consumed	8533.77	7967.86	4998.04	24081.02
	(b) Purchases of stock-in-trade	47.06	603.42	797.89	1734.63
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	161.70	69.91	7.43	27.77
	(d) Employee benefits expense	1474.29	1421.57	1215.27	5403.84
	(e) Finance Cost	266.06	288.67	276.00	1097.04
	(f) Depreciation and amortisation expense	499.17	526.08	475.98	1979.43
	(g) Other expenses	1916.28	1745.64	1710.82	7235.82
	Total expenses (IV)	12898.33	12623.15	9481.44	41559.54
V	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	3399.15	3164.89	1704.03	9032.21
VI	Exceptional items	00	00	00	82.94
VII	Profit / (Loss) before Tax (V-VI)	3399.15	3164.89	1704.03	8949.27
VIII	Tax expense				
	(1) Current tax	864.97	824.22	435.89	2280.03
	(2) Deferred tax	-28.50	-184.58	74.92	-88.70
	(3) Income tax relating to earlier years	00	-3.85	00	23.29
IX	Profit/(Loss) after Tax (VII-VIII)	2562.68	2529.11	1193.22	6734.66
X	Other Comprehensive Income (net of tax)				
	(i) Items that will not be reclassified to profit or loss	9.00	8.12	15.37	13.67
	(ii) Items that will be reclassified to profit or loss	00	00	00	00
	Total Other Comprehensive Income (net of tax)	9.00	8.12	15.37	13.67
XI	Total Comprehensive Income for the period (IX+X)	2571.68	2537.23	1208.59	6748.33
XII	Paid up Equity Share Capital (Face value Rs 10 each)	1037.62	1037.62	1037.62	1037.62
XIII	Other Equity (excluding evaluation reserve)				32219.62
XIV	Earnings per equity share (Non annualised) (In Rs)				
	(1) Basic	24.70	24.37	11.50	64.90
	(2) Diluted	24.70	24.37	11.50	64.90

FOR KWALITY PHARMACEUTICALS LIMITED

Date:- 10-08-2026
Place:- Amritsar

Ramesh Kumar
RAMESH KUMAR
Managing Director
DIN: 00462656



KWALITY PHARMACEUTICALS LIMITED
Regd. Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PUNJAB – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Unaudited Consolidated Financial Results for the Quarter Ended 30th June 2026

(₹ in lakhs) except EPS

Sr. No.	Particulars	Quarter Ended 30.06.2026 (Unaudited)	Quarter Ended 31.03.2026 (Audited)	Quarter Ended 30.06.2025 (Unaudited)	Year Ended 31.03.2026 (Audited)
I.	Revenue from operations (Net)	16235.22	15711.36	11147.90	50308.34
II.	Other income	62.27	105.80	37.57	285.86
III.	Total Revenue (I+II)	16297.49	15817.17	11185.47	50594.19
IV.	Expenses				
	(a) Cost of materials consumed	8533.77	7967.86	4998.04	24081.02
	(b) Purchases of stock-in-trade	47.06	603.42	797.89	1734.63
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	161.70	96.59	7.43	27.77
	(d) Employee benefits expense	1474.39	1421.67	1215.48	5404.26
	(e) Finance Cost	266.06	288.67	276.00	1097.04
	(f) Depreciation and amortisation expense	499.47	526.43	476.46	1981.04
	(g) Other expenses	1916.33	1745.69	1711.38	7236.28
	Total expenses (IV)	12898.78	12650.33	9482.69	41562.04
V.	Profit before share of profit of equity accounted investees, exceptional items and tax	3398.70	3166.83	1702.78	9032.16
VI.	Share of profit/(loss) of associates and joint ventures accounted for using equity method (net of income tax)	0.00	0.00	0.00	0.00
VII.	Profit before exceptional items and tax	3398.70	3166.83	1702.78	9032.16
VIII.	Exceptional items	00	00	00	82.94
IX.	Profit / (Loss) before Tax (VII-VIII)	3398.70	3166.83	1702.78	8949.21
X.	Tax expense:				
	(1) Current tax	864.97	824.22	435.89	2280.03
	(2) Deferred tax	- 28.50	- 184.58	74.92	- 88.70
	(3) Income tax relating to earlier years	00	- 3.85	00	23.29
	(4) MAT Credit (Entitlement)/Utilised	0.00	0.00	0.00	0.00
XI.	Profit/(Loss) after Tax (IX-X)	2562.23	2531.05	1191.97	6784.60



XII	Other Comprehensive Income				
	(i) Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of defined benefit plans(net Tax)	9.00	13.67	15.37	13.67
	(ii) Items that will be reclassified to profit				
	Exchange differences in translating financial statements of	00	06	- 26	- .23
	tax)	9.00	13.73	15.11	13.44
	Total Comprehensive Income for the period (XI+XII)	2571.23	2544.78	1207.08	6748.04
XIII	Profit/(loss) attributable to:				
	a) Owners of the Company	2562.45	2530.10	1192.58	6734.63
	b) Non-controlling interests	- 22	95	- 61	- 03
XIV	Other comprehensive income attributable to:				
	a) Owners of the Company	9.00	13.73	15.11	13.44
	b) Non-controlling interests				
XV	Total comprehensive income attributable to:				
	a) Owners of the Company	2571.45	2543.83	1207.69	6748.07
	b) Non-controlling interests	- 22	95	- 61	- 03
XVI	Paid up Equity Share Capital (Face value)	1037.62	1037.62	1037.62	1037.62
XVII	Other Equity(excluding revaluation reserve)				32041.94
XVIII	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	24.69	24.39	11.49	64.90
	(2) Diluted	24.69	24.39	11.49	64.90

*Basic and Diluted EPS for all periods except for year ended 31st March 2026 is not annualised

Date:- 10-08-2026

Place:- Amritsar

KWALITY PHARMACEUTICALS LTD.

RAMESH KUMAR
Managing Director
DIN: 00462656





CIN No. L24232PB1983PLC005426

D.L. No. 1800-OSP, 1804-B

GST No. 03AAACK6458M1ZB

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitiypharma.com
ramesh@kwalitiypharma.com
Website : www.kwalitiypharma.com

Notes:

1. The Financial Results of the Company for the Quarter Ended June 30, 2026 have been reviewed by the Audit Committee on 10th August, 2026 and approved by the Board of Directors of the Company in their meeting held on 10th August, 2026. The statutory auditors have carried out limited review of the results for the quarter ended 30th June, 2026 and have issued an unmodified review report.
2. The Financial Results have been prepared in accordance with the requirements of Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind-AS 34") notified under section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter ended 30th June, 2026 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standards) Rules 2014 and hence no separate segment reporting is given.
4. Previous period figures have been regrouped/rearranged, wherever necessary, to correspond to current period's presentation.
5. The above Financial Results are also available on our website www.kwalitiypharma.com and Stock Exchange website www.bseindia.com.
6. The figures for the quarter ended 31st March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited published year-to-date figures upto 31st December 2025, being the date of end of the third quarter of the financial year ended 31st March 2026 which were reviewed by the statutory auditors.
7. The Earning per Share (EPS) has been calculated as per Accounting Standard on Earning Per Share (AS 20).

FOR AND ON BEHALF OF THE BOARD
For KWALITY PHARMACEUTICALS LIMITED

Ramesh Kumar
Managing Director
DIN: 00462656



Date: 10-08-2026

Place: Amritsar